#Sweden #Peptide Synthesis #Uppsala #Asahi Kasei #PeptiSystems

PeptiSystems and Asahi Kasei Join Forces for Peptide Synthesis Advancement

In a significant development for the biotechnology sector, PeptiSystems, a company recognized for its cutting-edge manufacturing solutions in peptide and oligonucleotide drugs, has announced an exclusive global partnership with Asahi Kasei Bioprocess America (AKBA). This collaboration aims to enhance the capabilities of peptide synthesis, combining the technological strengths of both companies.

Strengthening Manufacturing Capabilities

PeptiSystems has established itself as a leader in developing innovative manufacturing solutions, focusing on the synthesis of complex peptide and oligonucleotide therapeutics. Their flow-through instrument platform is a core component of this strategy, enabling more efficient synthesis processes. Partnering with AKBA, a renowned provider of advanced bioprocessing equipment, allows PeptiSystems to leverage AKBA's high-performance column technology.

In this exclusive agreement, PeptiSystems plans to integrate the THESYS® ACS Ergo synthesis column into its large-scale peptide synthesis platform, dubbed the PeptiPro®. This integration promises to streamline operations, resulting in shorter turnaround times between production batches while maintaining rigorous safety and quality standards. As a result, users can expect higher efficiency and productivity, with the production process becoming not only faster but also more reliable.

A Comprehensive Solution for Clients

Karin Granath, the CEO of PeptiSystems, emphasized the strategic significance of this partnership, stating, "By incorporating a proven and high-quality column into our synthesis platform, we can deliver a comprehensive, ready-to-use solution for our customers. This collaboration helps expedite development phases while simultaneously decreasing risk, providing a robust foundation for future advancements in both research and manufacturing arenas."

Chris Rombach, President of Asahi Kasei Bioprocess America, echoed this sentiment, noting, "This partnership marks a natural progression towards offering next-generation peptide solutions tailored for the TIDES market. By combining our column expertise with PeptiSystems' pioneering synthesis platform, we are poised to deliver an integrated solution that effectively meets our customers' needs."

Innovating the Future of Peptide Production

The proprietary technology developed by PeptiSystems optimizes synthesis efficiency and minimizes material wastage, adhering to the highest standards of quality and reproducibility. This strategic partnership is expected to empower pharmaceutical companies and contract development and manufacturing organizations (CDMOs) to scale their production capabilities for complex therapeutics, paving the way for advancements in next-generation manufacturing protocols.

The firm has consistently pursued innovation, integration, and customer value, positioning itself as a vital player in the biotechnology landscape. The integration of AKBA's column technology is a testament to PeptiSystems' commitment to reshaping the standards of peptide synthesis and manufacturing solutions.

In conclusion, the alliance between PeptiSystems and Asahi Kasei Bioprocess America not only marks a milestone in peptide manufacturing technology but also promises to usher in an era of enhanced production capabilities for the biotech industry. It stands as a robust example of how collaborative synergies can lead to groundbreaking innovations, ultimately benefiting customers and the healthcare ecosystem at large.